Las Vegas-based Synthesis Peptides, a U.S. veteran-owned supplier of research peptides, has announced that all 40-plus compounds in its catalog now ship with Certificates of Analysis (COAs) from external laboratories. This expansion ensures that every batch is independently verified for analytical peptide purity using both high-performance liquid chromatography (HPLC) and mass spectrometry, a move that strengthens the documentation standards for researchers sourcing compounds for in vitro studies.
The dual-method testing approach is critical because it addresses two distinct aspects of compound quality. HPLC separates the peptide components to identify and quantify impurities, providing a purity percentage. Mass spectrometry confirms the molecular identity by measuring the mass-to-charge ratio of ionized particles, ensuring the correct peptide structure. Together, these methods give researchers a comprehensive analytical record that supports the reliability of their experimental outcomes.
By routing verification through independent third-party laboratories rather than relying solely on in-house analysis, Synthesis Peptides removes potential internal bias from the process. This decision provides research institutions, universities, and private labs with an objective data point when evaluating compound specifications. The COAs accompany each order, allowing scientists to assess the quality of compounds prior to experimental use.
The company's catalog includes a diverse range of peptide sequences relevant to ongoing scientific inquiry in fields where in vitro experimentation is standard. The testing protocol is uniform across all compounds, regardless of order volume, meaning that a single-unit purchase receives the same documentation as a bulk order. This consistency is designed to give researchers a predictable baseline when incorporating externally sourced peptides into their workflows.
Synthesis Peptides operates with a focus on the scientific research community, and its veteran-owned status reflects the organizational structure. The company emphasizes that all products are intended strictly for in vitro laboratory research use only and are not for human or animal consumption. Researchers can access compound listings and corresponding analytical documentation through the company's platform, where COA records are made available alongside product specifications.
This move toward full-catalog third-party verification underscores a commitment to transparency in the research peptide supply chain. By providing independently sourced purity data, Synthesis Peptides aims to support the scientific community's need for reliable, documented reagents. The company's dedication to rigorous testing standards is evident in this expansion, which ensures that every batch meets the same high-quality specifications.
